Virbac expands pet health portfolio with £100M acquisition of feline hyperthyroidism drug from Norbrook
Source: SeekingAlpha
2025-12-18 02:37:16 ET
Virbac ( VRBCF ) has bolstered its specialty pet health portfolio by acquiring a world-leading feline hyperthyroidism treatment from Norbrook, valued at approximately £100 million....
Read the full article on Seeking Alpha
For further details see:
Virbac expands pet health portfolio with £100M acquisition of feline hyperthyroidism drug from Norbrook
Ste Virbac Sa Ord
NASDAQ: VRBCF
VRBCF Trading
0.0% G/L:
$346 Last:
23 Volume:
$346 Open:
